Disease severity as measured by IGA

A clinically and significantly greater proportion of patients randomized to DUPIXENT® achieved an IGA 0 or 1 response from baseline to week 161

Proportion of patients who achieved clear or almost clear skin (IGA 0 or 1) at week 16 with DUPIXENT® vs. placebo (primary endpoint)1†

Showing the percentage of patients in the SOLO 1, SOLO 2 and CHRONOS trials who achieved clear or almost clear skin at Week 16, defined as an IGA score of 0 or 1, with a reduction of greater than or equal to 2 points on a 0 to 4 IGA scale. In the SOLO 1 trial, 37.9% DUPIXENT®-treated patients (n=224) versus 10.3% of placebo-treated patients (n=224) had clear or almost clear skin. The p for this comparison is less than 0.0001. In the SOLO 2 trial, 36.1% DUPIXENT®-treated patients (n=233) versus 8.5% of placebo-treated patients (n=236) had clear or almost clear skin. The p for this comparison is less than 0.0001. In the CHRONOS trial, 38.7% of patients treated with DUPIXENT plus topical corticosteroids (n=106) and 12.4% of patients treated with placebo plus topical corticosteroids (n=315) had clear or almost clear skin. The p value for this comparison is less than 0.0001.

Long-term efficacy in the 52-week CHRONOS trial:

Significantly more DUPIXENT® patients achieved clear or almost clear skin (IGA 0 or 1) at week 52 vs. placebo (36% vs. 13%, secondary outcome, p<0.0001)1,5†

† Patients achieving IGA 0 or 1 with a reduction of ≥2 points on a 0-4 IGA scale.

Investigator’s Global Assessment (IGA)

An IGA score reflects a physician’s assessment of the overall disease severity at a given timepoint on a 5 point severity scale from clear to very severe disease. This severity is assessed based on the following clinical characteristics: erythema, induration/papulation, lichenification, oozing/crusting.9

Patients in the DUPIXENT® clinical trials had a baseline IGA score of 3 (moderate AD) or 4 (severe AD).1,8,9

4

Severe
Disease

Marked erythema, marked induration/papulation, and/or marked lichenification. Oozing or crusting may be present.

3

Moderate
Disease

Clearly perceptible erythema, clearly perceptible induration/papulation, and/or clearly perceptible lichenification. Oozing or crusting may be present.

2

Mild
Disease

Slight but definite erythema, slight but definite induration/papulation, and/or slight but definite lichenification. No oozing or crusting.

1

Almost
Clear

Barely perceptible erythema, barely perceptible induration/papulation, and/or minimal lichenification. No oozing or crusting.
 

0

Clear
 

No signs of erythema, induration/papulation, lichenification, or oozing/crusting. Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.

A clinical responder was defined as a patient achieving an IGA 0 or 1 and at least a 2-point improvement from baseline.1

Not an actual patient.

Dosing and Administration

Thinking about prescribing DUPIXENT®? Find helpful information to get started.
 

START NOW

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.
 

REQUEST A VISIT
Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo

Contact Us
Terms & Conditions
Privacy Policy
Cookie Policy
Site Map

DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo